Clinical Framing
Recurrent urinary tract infections are among the most common complaints in postmenopausal women, and among the most reflexively managed. A positive dipstick, dysuria, and urgency get a 5-day antibiotic course. The infection resolves. Then it comes back. And again. At a certain point, the question that should be driving clinical decision-making, why does this keep happening, gets replaced by a standing prescription.
What that prescription does not address is the urogenital environment that keeps producing the same symptoms. In postmenopausal women, that environment is shaped by estrogen and androgen deficiency, a thinning epithelium, rising vaginal pH, and the progressive loss of Lactobacillus dominance that once kept the urogenital tract hostile to pathogens. Layer in the metabolic shifts of menopause and the microbiome disruption that accumulates with each antibiotic course, and what looks like a recurrent infection problem is often something else entirely.
This case illustrates what happens when a clinician stops treating the symptom and starts investigating the terrain. The answer was not a better antibiotic. It was an estrogen-deficient, dysbiotic urogenital environment that had never been properly assessed, let alone treated.
Patient Presentation
Patient: 50-year-old woman, postmenopausal for 2 years
Chief Complaint: Recurrent UTIs with 7 “episodes over the past 18 months, each treated with antibiotics
She was referred by her PCP after her fourth urine culture in a row returned negative or “mixed flora” despite classic symptoms of dysuria, urgency, frequency, and pelvic pressure. Her PCP was appropriately skeptical that ongoing antibiotic treatment was the right answer and wanted a functional medicine perspective on why these episodes kept recurring.
She was not on any hormone therapy when she came to the practice. She had been told her symptoms were “probably post-menopausal changes” but was not offered any treatment beyond a bladder training referral. She did not have “classic” symptoms of menopause and reports that “menopause was easy” for her. She described her vaginal tissue as dry, thin, and intermittently painful with any friction. Intercourse had been sparse with her partner for the last year.
Additional symptom history:
- Significant urgency and nocturia (2-3x per night) with no documented overactive bladder workup
- Mild stress incontinence with coughing and sneezing, worsening over the prior year
- Persistent low-grade pelvic discomfort between episodes
- Antibiotic history in the prior 12 months: 2x nitrofurantoin, 1x trimethoprim-sulfamethoxazole, 1x ciprofloxacin
- Fatigue, brain fog, and disrupted sleep attributed to nocturia
- No significant history of bladder structural abnormality, diabetes, or immunosuppression noted
She had not had a DEXA scan since age 50 and no hormone panel for over 5 years.
Diagnostic Workup
The initial objective was to establish what kind of urogenital environment we were dealing with—both microbiologically and hormonally—before making any treatment decisions. Standard urine culture had already demonstrated its limitations in this case. What was needed was more granular information.
Urogenital Microbiome: MicroGenDx NGS
Next-generation sequencing of a midstream urine sample was ordered through MicroGenDx. Unlike standard culture, NGS identifies and quantifies all microbial DNA present, including organisms that do not grow well in standard culture conditions and low-abundance commensals.
| Organism | Relative Abundance | Clinical Significance |
|---|---|---|
| Lactobacillus crispatus | < 1% | Severely depleted — protective dominant species absent |
| Lactobacillus iners | 9% | Low-abundance, weaker protective species |
| Gardnerella vaginalis | 31% | Elevated — associated with BV and UTI susceptibility |
| Prevotella bivia | 18% | Anaerobic dysbiosis marker |
| Escherichia coli | 6% | Present but below pathogenic threshold |
| Enterococcus faecalis | 4% | Low — opportunistic but not dominant |
| Ureaplasma urealyticum | 11% | Associated with urogenital inflammation |
| Mixed anaerobes (other) | 21% | Polymicrobial dysbiotic community |
This result was the critical clinical pivot point. There was no dominant uropathogen. What there was instead was a severely Lactobacillus-depleted urogenital microbiome—the exact environment that creates vulnerability to recurrent symptomatic episodes, inflammatory urethral irritation, and susceptibility to any transient bacterial challenge. Treating this picture with antibiotics was not only ineffective, it was actively worsening the dysbiosis with each course.
Hormone Panel
A comprehensive hormone panel was ordered, including reproductive hormones, adrenal markers, and thyroid function. Hormone testing had not been done for her in many years. Although this patient is post-menopausal and we expect to find post-menopausal hormone levels, we do want to check-in and assess the entire hormone picture.
| Marker | Result | Conventional Range | Notes |
|---|---|---|---|
| Estradiol (E2) | 8 pg/mL | < 20 pg/mL postmenopausal | Severely deficient — urogenital tissue health requires higher local estrogen |
| FSH | 82 mIU/mL | 25.8-134.8 mIU/mL | Confirms complete ovarian senescence |
| LH | 48 mIU/mL | 7.7-58.5 mIU/mL | Elevated — consistent with postmenopausal state |
| Progesterone | < 0.1 ng/mL | < 0.5 ng/mL postmenopausal | Absent — baseline postmenopausal |
| Total Testosterone | 9 ng/dL | 8-48 ng/dL | Low-normal — contributes to tissue atrophy |
| Free Testosterone | 0.4 pg/mL | 0.6-6.7 pg/mL | Below functional range — urogenital androgen receptors affected |
| SHBG | 168 nmol/L | 19-148 nmol/L | Elevated — further reducing free testosterone availability |
| DHEA-S | 42 mcg/dL | 18-244 mcg/dL postmenopausal | Low — reduced adrenal androgen precursor pool |
Vaginal pH
Point-of-care vaginal pH testing: 6.4
Normal premenopausal vaginal pH is 3.8 to 4.5, maintained by Lactobacillus-produced lactic acid. This acidic environment is not incidental—it is the primary chemical barrier against urogenital pathogen colonization, and it depends entirely on adequate estrogen stimulating glycogen production in the vaginal epithelium, which Lactobacillus species then ferment into lactic acid.
At menopause, as estrogen declines and Lactobacillus communities thin out, vaginal pH typically rises into the 6.0 to 7.5 range. Any pH above 4.5 in a postmenopausal woman reflects estrogen deficiency at the tissue level and supports a clinical diagnosis of GSM—there is no special threshold to cross. What pH does tell us is degree. A reading in the low 5s suggests mild to moderate disruption. A reading of 6.4, as in this patient, reflects a urogenital environment that has shifted substantially toward alkalinity—one that is permissive for the anaerobic and gram-negative organisms seen on her NGS results, and hostile to the Lactobacillus recolonization needed to restore it.
In clinical practice, vaginal pH is an underused tool. It is inexpensive, takes seconds to perform, and provides direct tissue-level information that no blood panel can replicate. In a postmenopausal woman presenting with recurrent urogenital symptoms, a pH above 4.5 reframes the clinical question—away from which antibiotic to prescribe and toward what has happened to the hormonal and microbial environment that is supposed to be protecting this tissue.
Additional Markers
| Marker | Result | Reference | Notes |
|---|---|---|---|
| hsCRP | 1.8 mg/L | < 1.0 mg/L optimal | Elevated systemic inflammation |
| Fasting glucose | 99 mg/dL | < 100 mg/dL | Functionally elevated — explore metabolic dysfunction |
| HbA1c | 5.6% | < 5.7% | Prediabetic threshold — relevant for urinary glucose and infection risk |
| TSH | 3.5 mIU/L | 0.5-4.5 mIU/L conventional | Within conventional range; functionally elevated |
| Free T3 | 2.0 pg/mL | 3.0-4.0 pg/mL functional | Suboptimal/low — may contribute to tissue dryness and reduced mucosal integrity |
| 25-OH Vitamin D | 24 ng/mL | 40-80 ng/mL optimal | Deficient — relevant to immune defense and mucosal barrier function |
| Magnesium (RBC) | 5.4 mg/dL | 5.2-6.5 mg/dL optimal | Optimal |
Clinical Interpretation
The full picture that emerged from this workup was not a woman with an infection problem. It was a woman with a terrain problem, one that had been systematically worsened by repeated antibiotic exposure that depleted what little Lactobacillus protection remained. She is also experiencing a number of other imbalances, deficiencies and post-menopausal physiological changes that need addressing and support.
The root cause cascade:
- Severe estrogen and androgen deficiency produced significant urogenital epithelial atrophy, loss of tissue thickness, impaired vascularization, and reduced glycogen availability for Lactobacillus colonization
- The Lactobacillus-depleted urogenital environment (confirmed by NGS) allowed opportunistic organisms, particularly Gardnerella, Prevotella, and Ureaplasma, to dominate the microbiome, producing a proinflammatory polymicrobial community
- Vaginal pH of 6.4 confirmed complete loss of the acid-mediated antimicrobial barrier, eliminating a critical first-line defense against urogenital pathogens
- Each antibiotic course provided temporary partial symptom relief by reducing bacterial load, but further depleted Lactobacillus and accelerated the dysbiotic cycle
- Low free testosterone compounded the atrophy picture, androgen receptors in urogenital tissue are independent mediators of tissue integrity and pain sensitivity
- Vitamin D deficiency undermined local innate immune function; suboptimal free T3 contributed to mucosal barrier compromise; mildly elevated hsCRP indicates low grade systemic inflammation driven by unknown cause
- Fasting insulin of 13.5 with a fasting glucose of 99 and HbA1c of 5.6% indicates insulin resistance, not an incidental finding in a postmenopausal woman. Estrogen withdrawal directly reduces insulin sensitivity, impairs metabolic flexibility, and promotes visceral adiposity.
- TSH of 3.5 with free T3 of 2.0 pg/mL sits within conventional limits but falls short when it comes to functional care and optimal hormone levels. Thyroid hormone does not drive urogenital pathology directly, but postmenopausal women are also at increased risk for thyroid dysfunction, and symptom overlap with estrogen deficiency means it is frequently missed.
The symptomatic episodes this patient experienced were not classic ascending UTIs. They were inflammatory events driven by a dysbiotic, atrophied urogenital environment, with low-level bacterial stimulation sufficient to produce symptoms without constituting true infection. This distinction has direct treatment implications.
Treatment Approach
We organized the treatment plan in three overlapping phases. As you can guess, no further antibiotics were prescribed. The goal was to restore the urogenital environment, not suppress its microbial inhabitants.
Phase 1: Hormonal Restoration (Months 1-3)
Given the severity of the findings and symptom burden, the primary intervention was local estrogen therapy the most well-evidenced intervention for GSM and recurrent urogenital symptoms in postmenopausal women.
- Vaginal estradiol or estriol cream: low-dose, applied vaginally daily for 2-3 weeks and then 3x per week ongoing. Local application minimizes systemic absorption while delivering tissue-level effect directly where it is needed
- Vaginal DHEA (prasterone): introduced alongside estradiol. DHEA is locally converted to both estradiol and testosterone within urogenital tissue, addressing the androgen deficiency component independently of systemic hormone exposure
- Discussion of systemic MHT to include estradiol, progesterone and testosterone were discussed and incorporated in phase 2.
Phase 2: Urogenital Microbiome Rehabilitation (Months 2-4)
Restoring Lactobacillus dominance was a parallel and equally critical goal. Hormone restoration improves the epithelial substrate; microbiome rehabilitation directly reseeds the protective community.
- VS-01 Synbiotic: Insert vaginally per instructions, alternating nights with estradiol application
- Oral L. rhamnosus and L. reuteri RC-14 supplementation daily: evidence supports urogenital microbiome benefit from oral intake through urogenital recirculation
- D-mannose supplementation: 2g daily as ongoing prophylaxis—reduces E. coli binding to urogenital epithelium without antibiotic exposure
- Boric acid vaginal suppositories if needed twice weekly for the first 8 weeks, to restore acidic pH and suppress dysbiotic anaerobic growth while Lactobacillus recolonizes
- Consider oral L-ornithine 2-3 grams nightly with PH testing every morning for ph balancing (Ruth Kriz protocol)
- The patient wanted to pursue systemic MHT within 3-4 weeks of treatment intervention after discussing the pros and cons of treatment. The patient elected to add transdermal estradiol, oral micronized progesterone and transdermal testosterone for sleep, mood, and bone protection. A repeat DEXA was ordered given 8 years without bone density assessment.
Phase 3: Systemic Support and Optimization (Months 1-6)
- Vitamin D3/K2 5000 IU: targeting serum 25-OH Vitamin D of 60-80 ng/mL
- CGM monitoring to assess blood sugar imbalances
- Dietary guidance focused on reducing refined carbohydrate load, increasing good fats, increasing fiber with an overnight fast of 12-14 hours and a refeeding in the morning of 30-40 grams of protein
- Thyroid support: free T3 monitored; selenium and zinc introduced to support thyroid hormone conversion, recheck in 2 months
- Referral for pelvic floor physical therapy given stress incontinence and nocturia: structural contribution to symptoms warranted independent evaluation
- Recheck labs in 3 months to assess for nutrient replenishment and hormone replacement therapy monitoring
Follow-Up and Outcomes
6-Week Reassessment
- Vaginal tissue dryness and discomfort significantly reduced, patient described tissue as “less raw, more normal”
- Nocturia reduced from 2-3x per night to 1x per night
- No UTI episode since initiation
- Tolerating vaginal estradiol and DHEA without adverse effects
3-Month Reassessment
Repeat vaginal pH: 4.8 (down from 6.4 at baseline). This single marker reflected a fundamentally different urogenital environment.
| Marker | Baseline | 3 Months | Change |
|---|---|---|---|
| Vaginal pH | 6.4 | 4.8 | Significant improvement |
| Estradiol (E2) | 8 pg/mL | 52 pg/mL | Transdermal estradiol 0.5 mg introduced |
| Free Testosterone | 0.4 pg/mL | 35 pg/mL | Improving with DHEA and transdermal testosterone |
| DHEA-S | 42 mcg/dL | 58 mcg/dL | Upward trend |
| hsCRP | 1.8 mg/L | 0.9 mg/L | Improved |
| 25-OH Vitamin D | 24 ng/mL | 52 ng/mL | Now in optimal range |
- No UTI episodes in 3 months—first infection-free quarter in over two years
- Stress incontinence frequency reduced by approximately 50% per patient report
- Brain fog and fatigue improving, attributed partly to improved sleep from reduced nocturia and MHT introduction.
6-Month Reassessment
MicroGenDx NGS was repeated at 6 months to assess microbiome response to treatment.
| Organism | Baseline | 6 Months |
|---|---|---|
| Lactobacillus crispatus | < 1% | 54% |
| Lactobacillus iners | 9% | 18% |
| Gardnerella vaginalis | 31% | 6% |
| Prevotella bivia | 18% | 2% |
| Escherichia coli | 6% | 3% |
| Ureaplasma urealyticum | 11% | 4% |
| Mixed anaerobes (other) | 21% | 13% |
L. crispatus had gone from near-absent to dominant—a profoundly different microbiome. The dysbiotic community had been substantially displaced. The patient remained free of UTI episodes throughout the full 6-month follow-up period. She had not required a single antibiotic course.
Clinical Takeaway
This case demonstrates a clinical pattern that is far more common than it is recognized: recurrent urogenital symptoms in postmenopausal women that have been repeatedly misattributed to bacterial infection, managed with antibiotics, and worsened with each course.
The functional medicine approach is a root cause, systems based approach that looks at the bigger picture and takes into account all the potential contributors. It involved a decision to investigate the terrain rather than suppress the symptoms, to ask why Lactobacillus was absent rather than which antibiotic to use next. Once the root cause picture was clear, severe GSM, profound estrogen and androgen deficiency, and a fully disrupted urogenital microbiome, the treatment approach became clear.
Several elements of this case are worth internalizing for clinical practice:
- Standard urine culture has significant limitations in postmenopausal women. A negative or mixed-flora result in a symptomatic patient is not a diagnosis, it is a signal that something else is driving the presentation. NGS-level urogenital microbiome assessment provides information that culture cannot.
- Vaginal pH testing is inexpensive and accessible. This along with a thorough intake can tell you a lot about the urogenital hormonal environment. This should be standard in the workup of any postmenopausal woman with recurrent urogenital symptoms.
- The Lactobacillus-GSM-estrogen deficiency axis is the central pathophysiological thread in most postmenopausal recurrent UTIs. Local vaginal estrogen and DHEA therapy addresses this axis with a favorable safety profile and is evidence led.
- Antibiotic exposure in the context of urogenital dysbiosis compounds the underlying problem. Each course further depletes what protective microbiome remains. Breaking this cycle and restoring the terrain is vital to success.
- Androgens are independent mediators of urogenital tissue integrity and pain sensitivity, their deficiency is not captured by estrogen assessment alone. This is why a thorough investigation is important and learning what labs to test can be critical to rounding out care.
The clinical gaps this case exposes, missed metabolic dysregulation, undertreated urogenital atrophy, reflexive antibiotic prescribing, thyroid findings that never get acted on, are not gaps in a practitioner’s dedication. They are gaps in training. Conventional medical education does not teach clinicians how to assess the urogenital microbiome, sequence local versus systemic hormone therapy, interpret a functional hormone panel, or connect metabolic health to hormone decline.
Functional Hormone Mastery was built to close those gaps. The program covers how to prescribe and troubleshoot hormone therapy using an evidence-based framework, including how to initiate and titrate BHRT, manage common clinical challenges like paradoxical responses and symptom recurrence, and navigate the nuances of different delivery methods and formulations. But it goes beyond prescribing. The training teaches a root-cause approach to the full scope of hormonal change across the perimenopause and postmenopause transition, so you can assess and treat the whole patient, not just the hormone levels. If you want a systematic framework that makes cases like this navigable rather than frustrating, this is where that training lives.
